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Methylation-speciﬁc PCR (MSP) of the mouse p53 gene has not yet been reported. We searched the CpG islands, sequenced the
bisulﬁted DNA, and designed PCR primers for methylation and unmethylation sites. DNA from a young mouse produced a strong
PCR product with the unmethylated primer and a weaker band with the methylated primer. DNA from an old mouse produced
bands of similar intensities with both primers. In radiation-induced tumors, DNA from an old mouse yielded similar bands with
both types of primers. We suggest that MSP is a valuable technique for the epigenetic study of the mouse p53 gene.
1.Introduction
A number of speciﬁc loci have been described as becoming
hypermethylated during aging or carcinogenesis [1]. Most
remaining CpG sites are normally methylated in adult cells.
Transcriptional inactivation by cytokine methylation at pro-
moter CpG islands of tumor suppressor genes is thought to
be an important mechanism in human carcinogenesis [2]. In
half of all primary human cancer cells, p53 is the most com-
monly mutated tumor suppressor gene [3]. Moreover, p73, a
p53 homologue, has been shown to be hypermethylated in
leukemia [4]. Using human cancer cells, Herman and co-
workers [5] ﬁrst described methylation-speciﬁc PCR (MSP),
which can rapidly assess the methylation status of virtually
any group of CpG sites. The MSP primer sequences for the
human p53 gene have been identiﬁed in medulloblastomas
[6], human gliomas [7], and hepatocellular carcinoma [8].
While there are many mouse experiments, the MSP primer
sequences for the mouse p53 gene have yet to be reported. It
is thought that it helps a future study very much to establish
MSP technique. In this study, to establish MSP for this gene,
we analyzed a CpG site in the mouse p53 gene and designed
the corresponding primer sequences.
2.MaterialsandMethods
2.1. Experimental Animals. Mice carrying a disrupted, non-
functionalp53gene(p53−/−)werederivedfromhomologous
recombination in an embryonic stem cell line from 129/SvJ
mice as described previously [9, 10]. Wild type mice of the
parental inbred strain were used as controls for the p53+/+
mice. p53+/− mice were obtained by crossing male p53−/−
mice with female p53+/+ mice. The experimental protocols
were approved by the Ethics Review Committee for Animal
ExperimentationoftheUniversityofOccupationalandEnvi-
ronmental Health, Japan (Kitakyushu, Japan).
2.2. Irradiation. A 90Sr-90Y disk delivered a beta ray source
of 1.85 GBq at 15Gy/min. The backs of seven-week-old mice
(p53+/+ and p53+/−) were irradiated with beta rays three
times a week until the appearance of a tumor. These mice
received 5Gy/day.
2.3. Isolation of Genomic DNA. Genomic DNA from the
spleen, liver, kidney, and tumor was isolated using a Quick-
Gene DNA (Fujiﬁlm Holdings Corporation, Tokyo, Japan)
wholebloodkitaccordingtothemanufacturer’sinstructions.2 Molecular Biology International
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Figure 1: (a) CpG islands of the mouse p53 gene from exon 4 to exon 9. Underlined sequences indicate CpG islands that were searched
using Methyl Primer Express Software v1.0. The cytosine (C) surrounded by a rectangle is the CpG site. (b) The sequence of the CpG islands
after bisulﬁte conversion. The boxed area indicates the forward and reverse primer sets. Underline sequences refer to exons 5 and 6. (c)
Electropherograms of PCR products after subcloned plasmid DNA in 8-week-old and 122-week-old p53+/+ mice. In 8-week-old mice, a “C”
was converted to a “T”. In 122-week-old mice, a “C” was retained as a “C”.
2.4. Bisulﬁte Conversion. Approximately, 1µgo fD N Aw a s
treated with sodium bisulﬁte using an EpiTect Bisulﬁte kit
(Qiagen, Hilden, Germany) according to the manufactur-
er’s instructions. Brieﬂy, the DNA, bisulﬁte mix, and DNA
Protect buﬀe rw e r em i x e dt o g e t h e r .T h eb i s u l ﬁ t ec o n v e r s i o n
thermal cycling conditions were as follows: 99◦C for 5min,
60◦C for 25min, 99◦C for 5min, 60◦C for 85min, 99◦Cf o r
5min, and 60◦C for 175min. Finally, the bisulﬁte-converted
DNA was puriﬁed on a spin column and eluted with 20µLo f
EB buﬀer.
2.5. Ampliﬁcation of PCR Product. PCR primers were de-
signed using Methyl Primer Express Software v1.0 (Applied
Biosystems Inc. Foster City, CA, USA). PCR primer sets in-
cluded sense (5 -ATC GTT ATT CGG TTT GTT TTC-3 )
and antisense (5 -CAC GAC CTC CGT CAT ATA CT-3 )
primers. Thermal cycling conditions were as follows: 1 cycle
at 95◦C for 10min; 30 cycles at 94◦C for 15s, 55◦Cf o r3 0s ,
and 72◦C for 30s; 1 cycle at 72◦C for 10min.
2.6. Ligation, Transformation, and Sequence. PCR products
were inserted into a pcDNA 3.1/V5-His-TOPO vector by
TOPO cloning technology. The reaction was mixed gently
and incubated for 5 minutes at room temperature. Two mic-
roliters of this reaction mixture were then added to a tube of
TOP10 competent E. coli and mixed gently. After incubatingMolecular Biology International 3
Table 1: Primer sequences for p53 MSP analysis.
Primer sequence (5 –3 )
U1 F3 ATC GTT ATT CGG TTT GTT TTC
R4 CGA ACA CGA CTC CCA ACT AA
M2 F ATC GTT ATT CGG TTT GTT TTC
R CGA ACA CGA CTC CCA GCT AA
1U: un-methylated sequence; 2M: methylated sequence; 3F: forward se-
quence; 4R: reverse sequence.
on ice for 30 minutes, the cells were heat shocked for 30 sec-
onds at 42◦C without shaking. Tubes were immediately
transferred back to the ice, and 250µLo fr o o mt e m p e r a t u r e
medium was added. Afterincubation at 37◦Cf o r3 0m i n u t e s ,
reaction mixtures were spread onto a prewarmed ampicillin
plate and incubated overnight at 37◦C. Colonies were picked
and cultured overnight in LB medium containing 50µg/mL
ampicillin. We isolated the plasmid DNA using a miniprep
kit (Qiagen), and its sequence was analyzed using both the
T7 primer and reverse sequencing primers.
2.7.SequenceAnalysis. DNAsequencingwasperformedwith
a BigDye terminator v3.1 cycle sequencing kit (Applied Bio-
systems Inc.) according to the manufacturer’s instructions
using the T7 sequencing primer (Invitrogen, Carlsbad, CA,
USA)andthesenseprimer5 -TAA TAC GAC TCA CTA TAG
GG-3 . Thermal cycling conditions included 1 cycle at 96◦C
for 1min and 25 cycles at 96◦C for 10s, 50◦Cf o r5s ,a n d
60◦Cfor4min.TheDNAsequencingreactionswerepuriﬁed
using the BigDye XTerminator puriﬁcation kit (Applied Bio-
systems Inc.). The DNA sequencing reactions in 96 well
plates were run on a 3130/3130xl genetic analyzer (Applied
Biosystems Inc.), and resulting sequences were analyzed with
sequencing analysis software (Applied Biosystems Inc.).
2.8. Methylation Speciﬁc PCR (MSP). We searched for CpG
islands in the p53 gene and designed PCR primer sets using
Methyl Primer Express Software v1.0 (Applied Biosystems
Inc.). PCR ampliﬁcation was performed using an EpiTect
MSP kit (Qiagen). Thermal cycling conditions were as fol-
lows: 1 cycle at 95◦C for 10min; 35 cycles at 94◦Cf o r1 5s ,
50◦Cf o r1m i na n d7 2 ◦C for 30s; 1 cycle at 72◦C for 10min.
3. Results andDiscussion
3.1. Mapping of DNA Methylation Patterns in a CpG Islands of
the Mouse p53 Gene and the Sequence of Bisulﬁted DNA. We
searched the mouse p53 gene from exon 4 to 9 for a CpG is-
lands using Methyl Primer Express Software v1.0 (Figure
1(a); Applied Biosystems Inc.) and found one located from
intron 5 to intron 7, spanning 619 base pairs. The cytosine
(C) surrounded with a rectangle is the speciﬁc CpG site
(Figure 1(a)). This is the ﬁrst description of a CpG island for
the p53 gene in normal mouse tissues. Using the same soft-
ware, the CpG island was searched with simulated bisulﬁte-
converted DNA sequences. The resulting sequences were the
same as the sequences that were analyzed by the genetic
analyzer in this study.
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Figure 2: MSP analysis. Primer sets used for ampliﬁcation are
designated as unmethylated (U) and methylated (M). Liver, kidney,
and spleen samples were from two 8-week-old mice and two 122-
week-old p53+/+ mice. Tumors were induced by a 90Sr-90Yb e t ar a y
in p53+/+ and p53+/− mice.
Several candidates for PCR primer sets were given by the
software, and the suitable set, determined after many rounds
of PCR, included a methylated base. The best sets for p53-
unmethylation and p53-methylation are surrounded by a
rectangle in Figure 1(b) and given in Table 1. Cytosine (C) of
GCT (Alanine) in exon 5 was converted to a thymidine (T)
after bisulﬁte treatment in young mice, which did not occur
in old mice after the same treatment (Figures 1(b), 1(c)).
3.2. MSP Analysis. In all organs (i.e., liver, kidney, and
spleen) of 8-week-old mice, we obtained a strong PCR prod-
uct using the unmethylated primer and weaker band with
the methylated primer. Alternatively, in liver andspleen from
122-week-old mice, the DNA was ampliﬁed to similar PCR
products with both the unmethylated and methylated prim-
ers (Figure 2).
In radiation-induced tumors from p53+/+ mice and
p53+/− mice, ampliﬁed DNA yielded similar bands with both
the methylated and unmethylated primers (Figure 2)e x c e p t
in one tumor from a p53+/− mouse, which showed a strong
band with the former and a weaker band with the latter.
We have previously shown data for MSP in the p53 gene
[11] where p53 methylation increased with age in the spleen
after irradiation at a young age. After DNA damage is in-
duced by intra- and/or extracellular processes, DNA methy-
lation is known to increase with increasing age [12]. In this
study, we have shown how p53 methylation in the spleen and
liver relates to age and that p53 methylation was found in all
radiation-induced tumors in mice. Finally, it is interesting to
note that methylation increases in tumor suppressor genes in
h u m a nt u m o r sa sw e l l[ 13], including the p53 gene [6–8].
Inthisstudy,weestablishedMSPforthemousep53gene,
and this is the ﬁrst description. Unfortunately, we were only
able to ﬁnd one base (C) that was methylated, observing4 Molecular Biology International
bands of similar intensity using both unmethylated and
methylated primers. Therefore, there is still room for im-
provement in this MSP method. However, we could show
MSP technique for mouse p53. The technique is so simple
andeasy.Itisthoughtthatthewidthofthemethylationstudy
will progress in future by MSP technique for the mouse p53
gene having been established.
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